Advertisement
Screener

Edgewise Therapeutics, Inc. (EWTX) Overview

Edgewise Therapeutics, Inc. (EWTX) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.53; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.46; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -0.39; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -0.34; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$16.24$20.39$25.62$32.18$40.42$50.772025-11-062026-11-06$5.23$8.25$12.99$20.46$32.23$50.772021-11-082026-11-06$5.23$8.25$12.99$20.46$32.23$50.772021-03-262026-11-06$5.23$8.25$12.99$20.46$32.23$50.772021-03-262026-11-06$5.23$8.25$12.99$20.46$32.23$50.772021-03-262026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$45.08
Previous close
$39.19
Change
$5.89
Change (%)
15.03%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

EWTX
+57.90%
S&P 500
(m)

1 year

EWTX
+148.83%
S&P 500
(m)

3 years

EWTX
+583.94%
S&P 500
(m)

5 years

EWTX
+130.53%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.53

-0.61-0.50-0.39-0.27-0.1631 Mar 2025: estimate (m); actual -0.4331 Mar 2025(m)30 Jun 2025: estimate (m); actual -0.3430 Jun 2025(m)30 Sept 2025: estimate (m); actual -0.3930 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.4631 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.5330 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.53(m)(m)
1 Jan 202631 Mar 2026(m)-0.46(m)(m)
1 Jul 202530 Sept 2025(m)-0.39(m)(m)
1 Apr 202530 Jun 2025(m)-0.34(m)(m)
1 Jan 202531 Mar 2025(m)-0.43(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -1.63

-1.71-1.52-1.33-1.15-0.9631 Dec 2021: estimate (m); actual -1.1431 Dec 2021(m)31 Dec 2022: estimate (m); actual -1.2631 Dec 2022(m)31 Dec 2023: estimate (m); actual -1.5731 Dec 2023(m)31 Dec 2024: estimate (m); actual -1.4531 Dec 2024(m)31 Dec 2025: estimate (m); actual -1.6331 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-1.63(m)(m)
1 Jan 202431 Dec 2024(m)-1.45(m)(m)
1 Jan 202331 Dec 2023(m)-1.57(m)(m)
1 Jan 202231 Dec 2022(m)-1.26(m)(m)
1 Jan 202131 Dec 2021(m)-1.14(m)(m)

Revenue vs. Earnings

USD

No complete retained periods.

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$45.08(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$45.08High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning EWTX

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
146.00
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
1.64M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-11.95%*
Total return · month
-8.35%*
Total return · quarter
-4.23%*
Total return · half year
27.08%*
Total return · year to date
57.90%*
Total return · 1 year
148.83%*
Total return · 3 years
583.94%*
Total return · 5 years
130.53%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

Edgewise Therapeutics, Inc. Overview

View more →

(m)

(m)

SEC CIK
1710072
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
1715 38TH ST, BOULDER, Colorado, 80301, United States
Fiscal year end
1231
Phone
720-262-7002

Similar stocks

Stock NameCountryMarket CapPE Ratio
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51
Indivior Pharmaceuticals, Inc. (INDV)$4.250B14.09
Tango Therapeutics, Inc. (TNGX)United States$4.154B-42.53
Veradermics, Inc (MANE)United States$4.839B
AbCellera Biologics Inc. (ABCL)$3.879B-14.59
Erasca, Inc. (ERAS)United States$5.073B-19.96
Dianthus Therapeutics, Inc. /DE/ (DNTH)United States$5.082B-27.79
ACADIA PHARMACEUTICALS INC (ACAD)United States$3.823B11.45
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Xenon Pharmaceuticals Inc. (XENE)$3.684B-14.27